Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

Benzer Materyaller

• Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
  Yazar:: Freedman, Mark S., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
  Yazar:: Kappos, Ludwig, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
  Yazar:: Cohen, Jeffrey A, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
  Yazar:: Edan, G, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
  Yazar:: Miller David H, ve diğerleri
  Baskı/Yayın Bilgisi: (2011-02-01)